Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming

European Journal of Immunology

Volumn 44, Issue 8, 2014, Pages 2415-2424

  Fehres, Cynthia M ^a   Bruijns, Sven C M ^a   van Beelen, Astrid J ^a   Kalay, Hakan ^a   Ambrosini, Martino ^a   Hooijberg, Erik ^a   Unger, Wendy W J ^a   de Gruijl, Tanja D ^a   van Kooyk, Yvette ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvants; Aldara; Cross presentation; DCs; Human skin; T cell priming

Indexed keywords

CD40 ANTIGEN; CD70 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; MELAN A; PEPTIDE VACCINE; RESIQUIMOD;

ADJUVANT THERAPY; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; SKIN BIOPSY; VACCINATION;

ADJUVANTS; ALDARA; CROSS-PRESENTATION; DCS; HUMAN SKIN; T-CELL PRIMING;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; CYTOKINES; DENDRITIC CELLS; HUMANS; IMIDAZOLES; INJECTIONS, INTRADERMAL; LIGANDS; MART-1 ANTIGEN; MELANOMA; SKIN; TOLL-LIKE RECEPTOR 7;

EID: 84906078348     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201344094     Document Type: Article

References (44)

1. Smits, E. L., Ponsaerts, P., Berneman, Z. N. and Van, T. V., The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist. 2008. 13: 859-875.
2. Alving, C. R., Peachman, K. K., Rao, M. and Reed, S. G., Adjuvants for human vaccines. Curr. Opin. Immunol. 2012. 24: 310-315.
3. Duthie, M. S., Windish, H. P., Fox, C. B. and Reed, S. G., Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 2011. 239: 178-196.
4. Kawai, T. and Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010. 11: 373-384.
5. Manicassamy, S. and Pulendran, B., Modulation of adaptive immunity with Toll-like receptors. Semin. Immunol. 2009. 21: 185-193.
6. Kawai, T. and Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010. 11: 373-384.
7. Diebold, S. S., Kaisho, T., Hemmi, H. and Akira, S., Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004. 303: 1529-1531.
8. Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G. et al., Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004. 303: 1526-1529.
9. Gorden, K. K., Qiu, X., Battiste, J. J., Wightman, P. P., Vasilakos, J. P. and Alkan, S. S., Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J. Immunol. 2006. 177: 8164-8170.
10. Ito, T., Amakawa, R., Kaisho, T., Hemmi, H., Tajima, K., Uehira, K., Ozaki, Y. et al., Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. 2002. 195: 1507-1512.
11. Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdorfer, B., Giese, T., Endres, S. et al., Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002. 168: 4531-4537.
12. Crespo, M. I., Zacca, E. R., Nunez, N. G., Ranocchia, R. P., Maccioni, M., Maletto, B. A., Pistoresi-Palencia, M. C. et al., TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8alpha+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface. J. Immunol. 2013. 190: 948-960.
13. Baenziger, S., Heikenwalder, M., Johansen, P., Schlaepfer, E., Hofer, U., Miller, R. C., Diemand, S. et al., Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 2009. 113: 377-388.
14. Gaspari, A., Tyring, S. K. and Rosen, T., Beyond a decade of 5% imiquimod topical therapy. J. Drugs Dermatol. 2009. 8: 467-474.
15. Suchin, K. R., Junkins-Hopkins, J. M. and Rook, A. H., Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod. Arch. Dermatol. 2002. 138: 1137-1139.
16. Xiong, Z. and Ohlfest, J. R., Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. J. Immunother. 2011. 34: 264-269.
17. Mathers, A. R. and Larregina, A. T., Professional antigen-presenting cells of the skin. Immunol. Res. 2006. 36: 127-136.
18. Klechevsky, E., Morita, R., Liu, M., Cao, Y., Coquery, S., Thompson-Snipes, L., Briere, F. et al., Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008. 29: 497-510.
19. Klechevsky, E., Liu, M., Morita, R., Banchereau, R., Thompson-Snipes, L., Palucka, A. K., Ueno, H. et al., Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum. Immunol. 2009. 70: 281-288.
20. Haniffa, M., Shin, A., Bigley, V., McGovern, N., Teo, P., See, P., Wasan, P. S. et al., Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103 +nonlymphoid dendritic cells. Immunity 2012. 37: 60-73.
21. Segura, E., Valladeau-Guilemond, J., Donnadieu, M. H., Sastre-Garau, X., Soumelis, V., and Amigorena, S., Characterization of resident and migratory dendritic cells in human lymph nodes. J. Exp. Med. 2012. 209: 653-660.
22. Romani, N., Flacher, V., Tripp, C. H., Sparber, F., Ebner, S. and Stoitzner, P., Targeting skin dendritic cells to improve intradermal vaccination. Curr. Top. Microbiol. Immunol. 2012. 351: 113-138.
23. Lindenberg, J. J., Oosterhoff, D., Sombroek, C. C., Lougheed, S. M., Hooijberg, E., Stam, A. G., Santegoets, S. J. et al., IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation. PLoS One 2013. 8: e70237.
24. Banchereau, J., Thompson-Snipes, L., Zurawski, S., Blanck, J. P., Cao, Y., Clayton, S., Gorvel, J. P. et al., The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming. Blood 2012. 119: 5742-5749.
25. Schlitzer, A., McGovern, N., Teo, P., Zelante, T., Atarashi, K., Low, D., Ho, A. W. et al., IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 2013. 38: 970-983.
26. Santegoets, S. J., Bontkes, H. J., Stam, A. G., Bhoelan, F., Ruizendaal, J. J., van den Eertwegh, A. J., Hooijberg, E. et al., Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model. J. Immunol. 2008. 180: 4540-4549.
27. Angel, C. E., Lala, A., Chen, C. J., Edgar, S. G., Ostrovsky, L. L. and Dunbar, P. R., CD14 +antigen-presenting cells in human dermis are less mature than their CD1a +counterparts. Int. Immunol. 2007. 19: 1271-1279.
28. van der Aar, A. M., Sylva-Steenland, R. M., Bos, J. D., Kapsenberg, M. L., de Jong, E. C. and Teunissen, M. B., Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J. Immunol. 2007. 178: 1986-1990.
29. Oosterhoff, D., Heusinkveld, M., Lougheed, S. M., Kosten, I., Lindstedt, M., Bruijns, S. C., van, E. T. et al., Intradermal delivery of TLR agonists in a human explant skin model: preferential activation of migratory dendritic cells by polyribosinic-polyribocytidylic acid and peptidoglycans. J. Immunol. 2013. 190: 3338-3345.
30. de Gruijl, T. D., Sombroek, C. C., Lougheed, S. M., Oosterhoff, D., Buter, J. and van den Eertwegh, A. J., A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. J. Immunol. 2006. 176: 7232-7242.
31. Adams, S., O'Neill, D. W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C. M. et al., Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 2008. 181: 776-784.
32. Cho, K. A., Suh, J. W., Lee, K. H., Kang, J. L. and Woo, S. Y., IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1beta by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int. Immunol. 2012. 24: 147-158.
33. Cumberbatch, M., Dearman, R. J. and Kimber, I., Characteristics and regulation of the expression on interleukin 1 receptors by murine Langerhans cells and keratinocytes. Arch. Dermatol. Res. 1998. 290: 688-695.
34. Cannon, P. S., O'Donnell, B., Huilgol, S. C. and Selva, D., The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions. Br. J. Ophthalmol. 2011. 95: 1682-1685.
35. Cantisani, C., Lazic, T., Richetta, A. G., Clerico, R., Mattozzi, C. and Calvieri, S., Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat Inflamm. Allergy Drug Discov. 2012. 6: 65-69.
36. Patel, G. K., Goodwin, R., Chawla, M., Laidler, P., Price, P. E., Finlay, A. Y. and Motley, R. J., Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 2006. 54: 1025-1032.
37. Walter, A., Schafer, M., Cecconi, V., Matter, C., Urosevic-Maiwald, M., Belloni, B., Schonewolf, N. et al., Aldara activates TLR7-independent immune defence. Nat. Commun. 2013. 4: 1560.
38. Hendriks, J., Gravestein, L. A., Tesselaar, K., van Lier, R. A., Schumacher, T. N. and Borst, J., CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 2000. 1: 433-440.
39. Soares, H., Waechter, H., Glaichenhaus, N., Mougneau, E., Yagita, H., Mizenina, O., Dudziak, D. et al., A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J. Exp. Med. 2007. 204: 1095-1106.
40. Elgueta, R., Benson, M. J., de, V. V., Wasiuk, A., Guo, Y. and Noelle, R. J., Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 2009. 229: 152-172.
41. Nizzoli, G., Krietsch, J., Weick, A., Steinfelder, S., Facciotti, F., Gruarin, P., Bianco, A. et al., Human CD1c +dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood 2013. 122: 932-942.
42. de Gruijl, T. D., Luykx-de Bakker, S. A., Tillman, B. W., van den Eertwegh, A. J., Buter, J., Lougheed, S. M., van der Bij, G. J. et al., Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J. Immunol. 2002. 169: 5322-5331.
43. van Vliet, S. J., van, L. E., Geijtenbeek, T. B. and van Kooyk, Y., Differential regulation of C-type lectin expression on tolerogenic dendritic cell subsets. Immunobiology 2006. 211: 577-585.
44. Hooijberg, E., Ruizendaal, J. J., Snijders, P. J., Kueter, E. W., Walboomers, J. M., and Spits, H., Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J. Immunol. 2000. 165: 4239-4245.